查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1630989

全球硬化疗法市场：市场规模、份额和趋势分析（按药物、类型、应用、地区和细分市场，2025-2030 年）

Sclerotherapy Market Size, Share & Trends Analysis Report By Agents (Detergents, Chemical Irritants, Osmotic Agents), By Type (Ultrasound Sclerotherapy), By Application, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

硬化疗法市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，全球硬化疗法市场规模预计到 2030 年将达到 15 亿美元，2025 年至 2030 年期间的复合年增长率为 4.4%。硬化疗法是一种非侵入性手术，广泛用于治疗网状静脉、腿部毛细血管扩张和静脉曲张的主要治疗方法。此手术包括将溶液（硬化剂）直接注射到受影响的静脉中，有助于治疗疼痛、潮红、肿胀和痉挛等相关症状，并使其缩小并最终消失。应用部位的更好接触、微创技术的可用性、皮肤病学的进步以及静脉曲张和老年人口发病率的增加等因素正在推动市场的成长。

用于治疗静脉曲张的硬化剂分为清洗、高渗透压剂/渗透剂和化学刺激剂。十四烷基硫酸钠 (Sotradecol) 和聚多卡醇 (Asclera)、吗啉 (Scleromate) 和乙醇胺油酸酯 (Ethamoline) 等药物都是 FDA核准的硬化剂，用于治疗和减轻静脉损伤的影响。根据血管外科学会的数据，已开发国家超过 33.0% 的女性和约 17.0% 的男性因毛细血管扩张或静脉曲张而就医，仅在美国就影响到 35.0% 的人。

如果不及时治疗，这种疾病会导致严重的健康问题，包括慢性疼痛、深层静脉栓塞症、皮肤溃疡和冠状动脉疾病。根据 NCBI 统计，20.0% 的成年人在一生中的某个阶段会患上静脉曲张，老年人群和女性的发病率更高。预计这些因素将推动市场成长。然而，该手术的副作用，如色素沉着、毛髮脱落、疤痕和某些患者的过敏反应，可能会阻碍市场的成长。

硬化疗法市场：分析概述

  • 由于获得 FDA 高度核准、血栓形成风险低、有效性以及在医生中很受欢迎，清洗剂部门在 2024 年占据了市场主导地位，收益占有率为 43.5%。
  • 由于发泡硬化疗法比液体硬化疗法具有更高的领域曝光度和更好的效果，预计在预测期内泡沫硬化疗法领域将快速成长。
  • 北美硬化疗法市场占据全球市场主导地位，2024 年的收入份额为 44.5%，这归因于该地区对新技术的需求不断增加、大量关键参与者、静脉曲张患病率不断上升以及先进的医疗保健基础设施。
  • 预计预测期内亚太地区硬化疗法市场将达到最高的 5.7% 复合年增长率。

目录

第一章 分析方法及范围

第 2 章执行摘要

3. 硬化疗法市场：变数、趋势和范围

  • 市场联动展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTLE分析

第 4 章 硬化疗法市场：药物业务分析

  • 按药物类型市场占有率（2024 年和 2030 年）
  • 细分仪表板：按药物
  • 依药物类型分類的市场规模预测及趋势分析（2018-2030年）
  • 清洁剂
  • 化学刺激物
  • 渗透剂

第 5 章硬化疗法市场：按类型进行的业务分析

  • 按类型市场占有率（2024 年和 2030 年）
  • 细分仪表板：按类型
  • 按类型分類的市场规模预测及趋势分析（2018-2030）
  • 超音波硬化疗法
  • 液体硬化疗法
  • 泡沫硬化疗法

第 6 章 硬化疗法市场：按应用进行的业务分析

  • 按应用分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板：依用途
  • 按应用分類的市场规模预测和趋势分析（2018-2030 年）
  • 静脉曲张
  • 淋巴管畸形
  • 痔疮
  • 浮肿

第 7 章硬化疗法市场：按地区分類的估计和趋势分析

  • 各地区市场占有率（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 按国家/地区划分（2018-2030 年）
    • 美国
    • 加拿大
  • 欧洲
    • 按国家/地区划分（2018-2030 年）
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分（2018-2030 年）
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 按国家/地区划分（2018-2030 年）
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 市场参与企业：概览
  • 公司市场地位分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • LGM Pharma
    • Troikaa
    • Viatris Inc.
    • Omega Pharmaceuticals Pvt. Ltd.
    • Merz Pharma
    • ENDO-FLEX GmbH.
    • Perrigo Company plc
    • Medi-Globe GmbH
    • Medtronic
    • AngioDynamics
Product Code: GVR-4-68039-010-4

Sclerotherapy Market Growth & Trends:

The global sclerotherapy market size is estimated to reach USD 1.50 billion by 2030, expanding at a CAGR of 4.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Sclerotherapy is a non-invasive procedure that is widely used as a primary treatment for reticular veins, leg telangiectasias, and varicose veins. The procedure comprises injecting a solution (sclerosing agents or sclerosants) straight into the affected veins, which causes them to shrink and eventually disappear and assist in treating related symptoms such as aching, burning, swelling, and cramping. Factors like the better exposure to the site of application, utilization of less-invasive technologies, advances in dermatology, and increasing geriatric population with an incidence of varicose veins are fuelling the market growth.

Sclerosing agents used for the treatment of varicose veins are segmented into detergents, hyperosmolar/ osmotic agents, and chemical irritants. Agents like Sodium tetradecyl sulfate (Sotradecol) and Polidocanol (Asclera), Sodium morrhuate (Scleromate), Ethanolamine Oleate (Ethamoline) are all FDA approved sclerosants used to treat and reduce the effect of vein damage. According to the Society of Vascular surgery, more than 33.0% of women and about 17.0% of men consult a doctor for telangiectasias and varicose veins in industrialized countries, affecting up to 35.0% of people in the U.S. alone.

This condition, if left untreated can cause severe health problems such as chronic pain, deep vein clots, skin ulcers, and coronary ailments. According to NCBI, 20.0% of all adults will get varicose veins at some point in their lives and the prevalence is higher among the aging population and women. These factors are expected to boost the market growth. However, the side effects of this procedure such as hyperpigmentation and matting, scarring, and allergic reactions in some patients might hinder the market growth.

Sclerotherapy Market Report Highlights:

  • The detergents segment dominated the market with a revenue share of 43.5% in 2024 owing to high approvals by the FDA, low risk of clot formation, effectiveness, and its popularity among doctors
  • The foam sclerotherapy segment is anticipated to grow fast over the forecast period due to better exposure to the onsite and results than liquid sclerotherapy
  • North America sclerotherapy market dominated the global with a revenue share of 44.5% in 2024 owing to increasing demand for new technologies, a large pool of key players, rising prevalence of varicose veins, and advanced healthcare infrastructure in the region
  • Asia Pacific sclerotherapy market is expected to register the highest CAGR of 5.7% over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Agents
    • 1.2.2. Type
    • 1.2.3. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Sclerotherapy Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Sclerotherapy Market: Agents Business Analysis

  • 4.1. Agents Market Share, 2024 & 2030
  • 4.2. Agents Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Agents, 2018 to 2030 (USD Billion)
  • 4.4. Detergents
    • 4.4.1. Detergents Market, 2018 - 2030 (USD Billion)
  • 4.5. Chemical Irritants
    • 4.5.1. Chemical Irritants Market, 2018 - 2030 (USD Billion)
  • 4.6. Osmotic Agents
    • 4.6.1. Osmotic Agents Market, 2018 - 2030 (USD Billion)

Chapter 5. Sclerotherapy Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 5.4. Ultrasound Sclerotherapy
    • 5.4.1. Ultrasound Sclerotherapy Market, 2018 - 2030 (USD Billion)
  • 5.5. Liquid Sclerotherapy
    • 5.5.1. Liquid Sclerotherapy Market, 2018 - 2030 (USD Billion)
  • 5.6. Foam Sclerotherapy
    • 5.6.1. Foam Sclerotherapy Market, 2018 - 2030 (USD Billion)

Chapter 6. Sclerotherapy Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Billion)
  • 6.4. Varicose Veins
    • 6.4.1. Varicose Veins Market, 2018 - 2030 (USD Billion)
  • 6.5. Malformed Lymph Vessels
    • 6.5.1. Malformed Lymph Vessels Market, 2018 - 2030 (USD Billion)
  • 6.6. Hemorrhoids
    • 6.6.1. Hemorrhoids Market, 2018 - 2030 (USD Billion)
  • 6.7. Hydroceles
    • 6.7.1. Hydroceles Market, 2018 - 2030 (USD Billion)

Chapter 7. Sclerotherapy Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.3. Mexico
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Mexico Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.4. Argentina
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Regulatory Framework
      • 7.7.4.3. Competitive Insights
      • 7.7.4.4. Argentina Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. MEA
    • 7.8.1. MEA Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. LGM Pharma
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Agents Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Troikaa
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Agents Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Viatris Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Agents Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Omega Pharmaceuticals Pvt. Ltd.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Agents Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Merz Pharma
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Agents Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. ENDO-FLEX GmbH.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Agents Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Perrigo Company plc
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Agents Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Medi-Globe GmbH
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Agents Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Medtronic
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Agents Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. AngioDynamics
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Agents Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global sclerotherapy market, by region, 2018 - 2030 (USD Billion)
  • Table 4 Global sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 5 Global sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 6 Global sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 7 North America sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 8 North America sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 9 North America sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 10 North America sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 11 U.S. sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 12 U.S. sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 13 U.S. sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 14 Canada sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 15 Canada sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 16 Canada sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 17 Europe sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 18 Europe sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 19 Europe sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 20 Europe sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 21 UK sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 22 UK sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 23 UK sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 24 Germany sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 25 Germany sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 26 Germany sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 27 France sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 28 France sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 29 France sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 30 Italy sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 31 Italy sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 32 Italy sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 33 Spain sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 34 Spain sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 35 Spain sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 36 Norway sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 37 Norway sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 38 Norway sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 39 Denmark sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 40 Denmark sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 41 Denmark sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 42 Sweden sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 43 Sweden sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 44 Sweden sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 45 Asia Pacific sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 46 Asia Pacific sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 47 Asia Pacific sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 48 Asia Pacific sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 49 Japan sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 50 Japan sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 51 Japan sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 52 China sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 53 China sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 54 China sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 55 India sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 56 India sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 57 India sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 58 Australia sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 59 Australia sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 60 Australia sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 61 South Korea sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 62 South Korea sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 63 South Korea sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 64 Thailand sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 65 Thailand sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 66 Thailand sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 67 Latin America sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 68 Latin America sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 69 Latin America sclerotherapy market, by type, 2018 - 2030 (USD Billion
  • Table 70 Latin America sclerotherapy market, by application, 2018 - 2030 (USD Billion
  • Table 71 Brazil sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 72 Brazil sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 73 Brazil sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 74 Mexico sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 75 Mexico sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 76 Mexico sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 77 Argentina sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 78 Argentina sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 79 Argentina sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 80 Middle East & Africa sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 81 Middle East & Africa sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 82 Middle East & Africa sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 83 Middle East & Africa sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 84 South Africa sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 85 South Africa sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 86 South Africa sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 87 Saudi Arabia sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 88 Saudi Arabia sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 89 Saudi Arabia sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 90 UAE sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 91 UAE sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 92 UAE sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 93 Kuwait sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 94 Kuwait sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 95 Kuwait sclerotherapy market, by application, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Sclerotherapy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Agents outlook (USD Billion)
  • Fig. 10 Type outlook (USD Billion)
  • Fig. 11 Application outlook (USD Billion)
  • Fig. 12 Competitive landscape
  • Fig. 13 Sclerotherapy market dynamics
  • Fig. 14 Sclerotherapy market: Porter's five forces analysis
  • Fig. 15 Sclerotherapy market: PESTLE analysis
  • Fig. 16 Sclerotherapy market: Agents segment dashboard
  • Fig. 17 Sclerotherapy market: Agents market share analysis, 2024 & 2030
  • Fig. 18 Detergents market, 2018 - 2030 (USD Billion)
  • Fig. 19 Chemical irritants market, 2018 - 2030 (USD Billion)
  • Fig. 20 Osmotic agents market, 2018 - 2030 (USD Billion)
  • Fig. 21 Sclerotherapy market: Type segment dashboard
  • Fig. 22 Sclerotherapy market: Type market share analysis, 2024 & 2030
  • Fig. 23 Ultrasound sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 24 Liquid sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 25 Foam sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 26 Sclerotherapy market: Application segment dashboard
  • Fig. 27 Sclerotherapy market: Application market share analysis, 2024 & 2030
  • Fig. 28 Varicose veins market, 2018 - 2030 (USD Billion)
  • Fig. 29 Malformed lymph vessels market, 2018 - 2030 (USD Billion)
  • Fig. 30 Hemorrhoids market, 2018 - 2030 (USD Billion)
  • Fig. 31 Hydroceles market, 2018 - 2030 (USD Billion)
  • Fig. 32 Sclerotherapy market revenue, by region
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 39 Europe sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 44 France country dynamics
  • Fig. 45 France sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark sclerotherapy market, 2018 - 2030 (USD Billion
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 56 Asia Pacific sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 59 China country dynamics
  • Fig. 60 China sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 61 India country dynamics
  • Fig. 62 India sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 67 Thailand country dynamics
  • Fig. 68 Thailand sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 69 Latin America sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 72 Mexico country dynamics
  • Fig. 73 Mexico sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 76 MEA sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 83 Kuwait country dynamics
  • Fig. 84 Kuwait sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework